BioScrip (BIOS) Misses Q2 EPS by 14c, Revs Modestly Lower; Reiterates Outlook

BioScrip (NASDAQ: BIOS) reported Q2 EPS of ($0.26), $0.14 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $218.1 million versus the consensus estimate of $220.17 million.

2017 Guidance

The Company is reiterating its prior guidance of adjusted EBITDA in the range of $45.0 million to $55.0 million for full-year 2017. The Company is updating its revenue outlook for the year to a range of $815.0 million to $835.0 million, including the impact of the revised UnitedHealthcare contract. Additionally, the Company expects to incur restructuring expenses in a range of $11.0 million to $12.0 million, reflecting the ongoing restructuring activity that took place in the second quarter of 2017, and further expenses anticipated in the second half of 2017 primarily related to the impact of the revised UnitedHealthcare contract.

For earnings history and earnings-related data on BioScrip (BIOS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c